Skip to main content
Premium Trial:

Request an Annual Quote

Biogazelle Nabs $2.5M Investment to Develop Therapeutic RNA Targets

NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Ghent, Belgium-based Biogazelle said that it will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types and expand its commercial activities.

Biogazelle is a 2007 Ghent University spinout founded by CEO Jan Hellemans and CSO Jo Vandesompele. The company uses tools such as RNA sequencing, digital PCR, and its qbase+ software to provide gene expression analysis services.

"After a successful start period with an annual growth rate of 70 percent during which Biogazelle's qbase+ software was launched and a laboratory service was initiated, it was important to acquire additional funding to support the growth and internationalization of our commercial activities … and to start our own research programs," Hellemans said in a statement.

Vandesompele added in a statement that the company plans to "prioritize top candidate RNA targets, followed by high-throughput testing in our lab using anti-sense silencing technology."

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.